HER2 as a target for breast cancer therapy

Author： Tagliabue Elda   Balsari Andrea   Campiglio Manuela   Pupa Serenella M  

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.10, Iss.5, 2010-05, pp. : 711-724

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor

By Simonds Hannah M   Miles David  

Expert Opinion on Biological Therapy, Vol. 7, Iss. 4, 2007-04 ,pp. : 487-491

Informa Healthcare

Access to resources Recommend Favorite

Pertuzumab: evolving therapeutic strategies in the management of HER2-overexpressing breast cancer

By O'Sullivan Ciara C   Swain Sandra M  

Expert Opinion on Biological Therapy, Vol. 13, Iss. 5, 2013-05 ,pp. : 779-790

Informa Healthcare

Access to resources Recommend Favorite

Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer

By Burris Howard A  

Expert Opinion on Biological Therapy, Vol. 11, Iss. 6, 2011-06 ,pp. : 807-819

Informa Healthcare

Access to resources Recommend Favorite

Targeting Human Breast Cancer Cells That Overexpress HER-2/neu mRNA by an Antisense Iron Responsive Element

By Yan D-H.  

Biochemical and Biophysical Research Communications, Vol. 246, Iss. 2, 1998-05 ,pp. : 353-358

Elsevier

Access to resources Recommend Favorite

Increased HER2/neu expression in recurrent hormone receptor-positive breast cancer

By Kaklamani Virginia G.   Cianfrocca Mary   Ciccone Jennifer   Kindy Kelly   Rademaker Alfred   Wiley Elizabeth L.   Gradishar William   O’Regan Ruth M.  

Biomarkers, Vol. 15, Iss. 2, 2010-03 ,pp. : 191-193

Informa Healthcare

Access to resources Recommend Favorite